iTeos Therapeutics reported a net loss of $34.613 million for the first quarter of 2025, an improvement from a net loss of $38.216 million in the same period last year. This was primarily due to a decrease in total operating expenses, particularly in research and development, and a reduction in other expenses, despite lower grant and interest income.

iTeos Therapeutics reported a net loss of $43.7 million for the fourth quarter of 2024, compared to a net loss of $30.6 million in the same period of 2023. The company's cash and investments position stood at $655.0 million as of December 31, 2024, and is expected to provide runway through 2027.

iTeos Therapeutics reported a net loss of $13.5 million for the first quarter of 2021. The company's cash and cash equivalents totaled $321.4 million, expected to provide a runway into 2023.

iTeos Therapeutics reported its Q4 and full year 2020 financial results, highlighting a strong cash position of $336.3 million and progress in advancing its Phase 1/2a trials for inupadenant and EOS-448.

iTeos Therapeutics reported a net loss of $11.7 million for the third quarter of 2020, with a cash position of $340.0 million as of September 30, 2020. The company is focused on advancing its two lead candidates, EOS-850 and EOS-448, towards initial data readouts in the first half of 2021.

iTeos Therapeutics reported its Q2 2020 financial results, highlighting the completion of its IPO in July, which provided $210.6 million in net proceeds and extends the company's cash runway into 2023. Clinical trials for EOS-850 and EOS-448 are ongoing, with initial data expected in the first half of 2021.